Trial Profile
Pilot Study of 5 Azacytidine in the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukaemia With High-risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 27 Jun 2019 This trial has been Discontinued in UK - MHRA according to European Clinical Trials Database record.
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jun 2009 New trial record